About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (VRTX) has been publicly traded since 1991, making it a 35-year-old public company. It operates in the Biotechnology industry within the Healthcare sector. The company is headquartered in Boston, United States and employs approximately 6,400 people. With a market capitalization of $119 billion, VRTX is a large established company.
Key Statistics
- Current Price
- $474.92
- Market Cap
- $120.65B
- 52-Week High
- $519.68
- 52-Week Low
- $362.50
- Sector
- Healthcare
- Industry
- Biotechnology
$1,000 Invested
Monthly Returns Heatmap
Annual Returns
| Year | Return | Start | End |
|---|---|---|---|
| 2026 | +4.76% | $453.36 | $474.92 |
| 2025 | +12.58% | $402.70 | $453.36 |
| 2024 | -1.03% | $406.89 | $402.70 |
| 2023 | +40.90% | $288.78 | $406.89 |
| 2022 | +31.50% | $219.60 | $288.78 |
| 2021 | -7.08% | $236.34 | $219.60 |
| 2020 | +7.94% | $218.95 | $236.34 |
| 2019 | +32.13% | $165.71 | $218.95 |
| 2018 | +10.58% | $149.86 | $165.71 |
| 2017 | +103.42% | $73.67 | $149.86 |
| 2016 | -41.45% | $125.83 | $73.67 |
| 2015 | +5.92% | $118.80 | $125.83 |
| 2014 | +59.89% | $74.30 | $118.80 |
| 2013 | +77.33% | $41.90 | $74.30 |
| 2012 | +26.17% | $33.21 | $41.90 |
| 2011 | -5.20% | $35.03 | $33.21 |
| 2010 | -18.25% | $42.85 | $35.03 |
| 2009 | +41.05% | $30.38 | $42.85 |
| 2008 | +30.78% | $23.23 | $30.38 |
| 2007 | -37.92% | $37.42 | $23.23 |
| 2006 | +35.24% | $27.67 | $37.42 |
| 2005 | +161.78% | $10.57 | $27.67 |
| 2004 | +2.13% | $10.35 | $10.57 |
| 2003 | -34.70% | $15.85 | $10.35 |
| 2002 | -35.54% | $24.59 | $15.85 |
| 2001 | -65.61% | $71.50 | $24.59 |
| 2000 | +308.57% | $17.50 | $71.50 |
| 1999 | +17.65% | $14.88 | $17.50 |
| 1998 | -9.85% | $16.50 | $14.88 |
| 1997 | -18.01% | $20.12 | $16.50 |
| 1996 | +51.89% | $13.25 | $20.12 |
| 1995 | +76.67% | $7.50 | $13.25 |
| 1994 | -18.92% | $9.25 | $7.50 |
| 1993 | +89.74% | $4.88 | $9.25 |
| 1992 | -33.90% | $7.38 | $4.88 |
Valuation
VRTX currently trades at a trailing P/E ratio of 30.7, which is considered high relative to the broader market. The forward P/E of 21.4 suggests analysts expect earnings to be lower in the coming year. The price-to-book ratio stands at 6.4. The price-to-sales ratio is 9.9.
Dividends
Vertex Pharmaceuticals Incorporated does not currently pay a dividend, choosing to reinvest earnings back into the business for growth.
Risk & Volatility
VRTX has a beta of 0.32, indicating it is less volatile than the overall market. The stock's 52-week range is $362.50 to $517.20, and it currently trades in the upper half of its 52-week range.
Analyst Ratings
Based on 28 analyst opinions, VRTX has a consensus "buy" rating. The average price target of $545.50 suggests 16.2% upside from current levels.
Frequently Asked Questions
What does Vertex Pharmaceuticals Incorporated do? ▼
Vertex Pharmaceuticals Incorporated is a Biotechnology company operating in the Healthcare sector. The company is headquartered in Boston, United States.
What sector is VRTX in? ▼
VRTX operates in the Healthcare sector, specifically in the Biotechnology industry.
When did VRTX go public? ▼
Vertex Pharmaceuticals Incorporated went public in 1991, making it a 35-year-old public company as of 2026.
How much would $1,000 invested in VRTX 5 years ago be worth today? ▼
A $1,000 investment in VRTX five years ago would be worth approximately $2,219 today, representing a 121.9% return.
Does VRTX pay dividends? ▼
No, Vertex Pharmaceuticals Incorporated does not currently pay a dividend. The company reinvests its earnings into growth.
What is VRTX's market cap? ▼
Vertex Pharmaceuticals Incorporated has a market capitalization of $119 billion, classifying it as a large-cap company.
What is VRTX's P/E ratio? ▼
VRTX has a trailing P/E ratio of 30.7 and a forward P/E of 21.4, which measures how much investors are paying per dollar of earnings.
Is VRTX a buy, hold, or sell? ▼
Based on 28 opinions, VRTX has a consensus "buy" rating. The average price target is $545.5.
Last updated: 3/14/2026